Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis

Table 2

Characteristics of the eligible studies evaluating high miRNA expression levels in serum samples and patient survival data.

Study (year)	Country	Cancer	Stage	Test	Cut-off value	miRNA	Sample size	MFD	Newcastle-Ottawa Quality Assessment Scale
									Selection	Compatibility	Outcome
Antolín et al. (2015) [34]	Spain	BC	I–IV	qRT-PCR	ROC	200c/141	57	265 [235] w	★★★	★★	★★★
Lin et al. (2014) [35]	Australia	PrC	IV	qRT-PCR	Median	200b	97	62 m	★★★	★	★★★
Liu et al. (2014) [36]	China	HCC	I–IV	qRT-PCR	Median	200a	136	50 m	★★	★	★★
Zhu et al. (2014) [15]	China	NSCLC	I–IV	qRT-PCR	ROC	429	70	30 m	★★	★	★★
Yu et al. (2013) [37]	China	ESC	III-IV	qRT-PCR	Median	200c	157	50 m	★★	★★	★★
Tanaka et al. (2013) [38]	Japan	ESC	I–IV	qRT-PCR	Comparison w/normal group	200c	64	2 y	★★★	★	★★
Toiyama et al. (2014) [39]	Japan	CRC	I–IV	qRT-PCR	ROC	200c	321	60 m	★★★	★	★★
Valladares-Ayerbes et al. (2012) [40]	Spain	GC	I–IV	qRT-PCR	MeanComparison w/normal group	200c	52	60 m	★★★	★★	★★★
Cheng et al. (2011) [41]	China	CRC	I–IV	qRT-PCR	ROC	141 (Tianjin)	156/102	50/100 m	★★★	★	★★★
	USA					141 (TexGen)

[Value] indicates microRNA type or maximum follow-up duration for progression-free survival.
MFD: maximal follow-up duration, AST: astrocytoma, BC: breast cancer, CRC: colorectal cancer, EEC: endometrioid endometrial carcinoma, EOC: epithelial ovarian cancer, ESC: esophageal squamous cancer, GC: gastric cancer, HCC: hepatocellular carcinoma, OC: ovarian cancer, PC: pancreatic cancer, PrC: castration-resistant prostate cancer, NSCLC: non-small-cell lung cancer, ROC, receiver operating characteristic analysis, NA: not available, mo: months, wk: weeks, and y: years.
Study reporting both overall survival and progression-free survival data.